Regarding Patent Applications

Cyxone has licensed patent applications at various stages of approval in Europe, North America and Australia. In the US, our patent is approved and in other markets patent applications are well on the way to being approved. In Australia, our patent application was accepted in July, since when the company has submitted a final version and paid the required approval fee.

On October 5, the Australian patent office published a "certificate of grant". This means that our patent application is approved and that the agency is now able to issue a patent letter. Patent protection in this case lasts for 20 years to 2032.

It is usually Cyxone's policy not to publish information regarding patents prior to the issue of a patent letter.

October 6, 2017

Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0)723 816168
Adelgatan 21
211 22 Malmö

This is information that Cyxone AB is required to publish under the EU Market Abuse Directive. The information was provided under the auspices of the above contact person for publication on October 6, 2017 at 15:30 CET.

About Cyxone
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of substances that inhibit key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank, which can be reached on +46 (0) 8 46 38 000.


Documents & Links